Bipartisan Senate Bill Could Cap Insulin at $35 a Month

Americans struggling to afford life-saving insulin are one step closer to real relief, thanks to a bipartisan group of senators giving new life to legislation that could cap costs at $35 a month.

Senators Jeanne Shaheen, Susan Collins, Raphael Warnock, and John Kennedy have joined forces on the INSULIN Act of 2026. The bill would prevent health insurance plans from charging more than $35 for a 30-day supply of insulin starting in 2027.

The legislation builds on a 2022 law that capped insulin costs for Medicare patients. Now these senators want to extend that same protection to Americans with private insurance and employer-sponsored health plans.

Collins shared a powerful reminder of why this matters during a Senate hearing last week. She met with a young woman who ended up hospitalized after rationing her insulin because she couldn't afford the full cost. Stories like hers are why the senators refuse to give up on this fight.

The bill goes further than its earlier version. At the urging of Senators Kennedy and Warnock, it now includes a five-year pilot program in 10 states to help uninsured patients get insulin for no more than $35 a month. That means even people without insurance coverage could finally afford this essential medication.

The timing aligns with growing momentum to lower prescription drug costs across the board. President Trump has made drug pricing a priority, recently announcing agreements with nine pharmaceutical companies to reduce prices. His TrumpRx portal already lists Insulin Lispro from Eli Lilly at $25.

The Ripple Effect

This legislation could transform life for the estimated 8.4 million Americans who use insulin daily. When people can afford their medication, they avoid dangerous health emergencies and costly hospital stays. Families won't have to choose between groceries and life-saving medicine.

The bipartisan support sends a powerful message. Democrats and Republicans are proving they can work together on issues that directly improve people's lives. Collins chairs the Senate Diabetes Caucus alongside Shaheen, bringing years of expertise and dedication to this cause.

The bill authorizes $100 million for 2027 to make these cost reductions possible. Starting in 2028, patients would pay either $35 or 25% of the negotiated price, whichever is lower.

Senator Shaheen, who is serving her final year in the Senate, sees this as essential legacy work. She wants to leave knowing she helped address the costs of America's most expensive chronic disease.

Real people are counting on this legislation to move forward, and the cooperation between both parties gives genuine reason for hope.